AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Humacyte, Inc. Common Stock
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG00XPPT7T6
0.44▲ 0.02 (5.40%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
0.41
Day's Range
0.40 – 0.44
52-Week Range
0.34 – 1.78
Volume
2.6M
Avg Volume
5.5M
Share Statistics
Shares Outstanding
Employees
184
Exchange
XNAS
Listed
2021-08-27
Share count as of August 10, 2026

Humacyte, Inc. Common Stock (HUMA) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Humacyte, Inc. Common Stock (HUMA)
What is Humacyte, Inc. Common Stock's Market Cap?
Humacyte, Inc. Common Stock's Market Cap is $121.0M, based on as-reported figures from SEC (XBRL) filings.
What is Humacyte, Inc. Common Stock's Enterprise Value?
Humacyte, Inc. Common Stock's Enterprise Value is $107.2M, based on as-reported figures from SEC (XBRL) filings.
What is Humacyte, Inc. Common Stock's Price / Sales?
Humacyte, Inc. Common Stock's Price / Sales is 57.0×, based on as-reported figures from SEC (XBRL) filings.
What is Humacyte, Inc. Common Stock's EV / Revenue?
Humacyte, Inc. Common Stock's EV / Revenue is 50.6×, based on as-reported figures from SEC (XBRL) filings.
What is Humacyte, Inc. Common Stock's EV / EBITDA?
Humacyte, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Humacyte, Inc. Common Stock's Revenue (TTM)?
Humacyte, Inc. Common Stock's Revenue (TTM) is $2.1M, based on as-reported figures from SEC (XBRL) filings.
What is Humacyte, Inc. Common Stock's Net Income (TTM)?
Humacyte, Inc. Common Stock's Net Income (TTM) is -$96.7M, based on as-reported figures from SEC (XBRL) filings.
What is Humacyte, Inc. Common Stock's EBITDA?
Humacyte, Inc. Common Stock's EBITDA is -$105.8M, based on as-reported figures from SEC (XBRL) filings.
What is Humacyte, Inc. Common Stock's Diluted EPS (TTM)?
Humacyte, Inc. Common Stock's Diluted EPS (TTM) is -0.35, based on as-reported figures from SEC (XBRL) filings.
What is Humacyte, Inc. Common Stock's EBITDA Margin?
Humacyte, Inc. Common Stock's EBITDA Margin is -4988.0%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · HUMAAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue—
YoY growth+34.9%———
Operating expenses:
Cost of goods sold—
Research and development—
General and administrative———
Total operating expenses—
% of revenue6749.3%—6703.0%3339.0%
Loss from operations—
% of revenue-6649.3%—-6603.0%-3239.0%
Other income (expense), net
Interest income—
Interest expense—
Change in fair value of Contingent Earnout Liability—
Change in fair value of derivatives—
Total other (expense) income, net—
Net (loss) income and comprehensive (loss) income
% of revenue-9064.5%—-5311.3%-2325.4%
Net (loss) income per share attributable to common stockholders, basic—
Net (loss) income per share attributable to common stockholders, diluted—